IBUPROFEN OFF DRUGS LIST IN JAPAN
The Japanese Pharmaceutical Affairs Bureau has removed the non-steroidal anti-inflammatory drug ibuprofen (specifically all single-entity or combination products containing 150mg or less of the compound) from the list of designated drugs. This is the first time that an oral preparation has been removed from the list, which designates those drugs which can be made available only by qualified pharmacists.
Other products which have been removed from the designated drugs list in the past are the NSAID indomethacin and antifungals miconazole and econazole. The removal allows for the drugs to be sold by "second-class" or unqualified retailers, and it is estimated that this action generally expands the market for list-removed products by around 30%.
Over-the-counter versions of ibuprofen (SS Pharmaceutical's Eve and Kaken Pharmaceutical and Chugai Pharmaceutical's Chilka) have been available since 1985, and the overall market for all single-entity and combination ibuprofen products is around 10 billion yen ($94 million) a year, notes Pharma Japan.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze